Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

(2018) Tarik Asselah et al.   Clinical Gastroenterology and Hepatology

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

(2018) Namiki Izumi et al.   Hepatology International

EASL Recommendations on Treatment of Hepatitis C 2018

(2018) Jean-Michel Pawlotsky et al.   JOURNAL OF HEPATOLOGY

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

(2018) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

(2018) Preethi Krishnan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens

(2018) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

(2017) Fred Poordad et al.   HEPATOLOGY

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

(2017) Hidenori Toyoda et al.   HEPATOLOGY

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

(2017) Kazuaki Chayama et al.   JOURNAL OF GASTROENTEROLOGY

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

(2017) Goki Suda et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

(2017) Hiromitsu Kumada et al.   JOURNAL OF GASTROENTEROLOGY

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

(2017) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b

(2017) Nobuhiko Ogasawara et al.   JOURNAL OF MEDICAL VIROLOGY

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

(2017) Xavier Forns et al.   LANCET INFECTIOUS DISEASES

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings

(2017) Hitomi Sezaki et al.   LIVER INTERNATIONAL

Hepatitis C virus infection

(2017) Michael P. Manns et al.   Nature Reviews Disease Primers

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

(2016) Norah A. Terrault et al.   GASTROENTEROLOGY

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

(2016) Jean-Michel Pawlotsky   GASTROENTEROLOGY

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

(2016) Joji Toyota et al.   JOURNAL OF GASTROENTEROLOGY

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

(2016) Hiromitsu Kumada et al.   JOURNAL OF GASTROENTEROLOGY

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

(2016) Christoph Sarrazin   JOURNAL OF HEPATOLOGY

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis

(2015) Hiromitsu Kumada et al.   HEPATOLOGY

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

(2015) Masashi Mizokami et al.   LANCET INFECTIOUS DISEASES

Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b

(2014) Fiona McPhee et al.   ANTIVIRAL THERAPY

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial

(2014) Masao Omata et al.   JOURNAL OF VIRAL HEPATITIS

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

(2014) David B. Ascher et al.   Scientific Reports

IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin

(2013) Eric G. Meissner et al.   JOURNAL OF INFECTIOUS DISEASES

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

(2013) Ludmila Prokunina-Olsson et al.   NATURE GENETICS

Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease

(2012) Suguru Ogura et al.   HEPATOLOGY RESEARCH

Notice

(2012)   Kidney International Supplements

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

(2009) R. A. Love et al.   JOURNAL OF VIROLOGY

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

(2009) David L. Thomas et al.   NATURE

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS